BC Innovations | Nov 7, 2019
Targets & Mechanisms

New cereblon substrates linked to thalidomide teratogenicity

A Celgene-funded study from Tokyo Medical University and the University of Milan has identified two new thalidomide-dependent CRBN substrates that could be applied to screens for new, safer thalidomide derivatives. Thalidomide and its analogs, collectively...
BC Extra | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

Tessa is hoping a JV with a Guangzhou biohub will speed access to the company’s virus-specific T cell therapies for cancers prevalent in China. The Singapore-based company, which partnered Thursday with GSGKC to develop and...
BC Extra | Aug 3, 2018
Preclinical News

Mechanism identified behind thalidomide-induced birth defects

Researchers at Dana-Farber Cancer Institute uncovered the mechanistic pathway by which thalidomide and two related analogs cause severe fetal harm, answering a long-held question about the three teratogenic drugs now used as cancer therapies. The...
BC Week In Review | May 18, 2018
Company News

FDA names, shames ‘anticompetitive’ drug companies

FDA Commissioner Scott Gottlieb Thursday made public a list of 41 branded drug companies that generics manufacturers have accused of blocking access to drug samples to thwart development of competitive generic drugs. The list includes...
BC Extra | May 17, 2018
Politics & Policy

FDA names, shames ‘anticompetitive’ drug companies

FDA Commissioner Scott Gottlieb Thursday made public a list of 41 branded drug companies that generics manufacturers have accused of blocking access to drug samples to thwart development of competitive generic drugs. The list includes...
BioCentury | May 23, 2016
Product Development

Provoking a response

Gritstone Oncology Inc. selected Immune Design Corp .'s ZVex technology to deliver personalized neoantigen therapies because targeting the antigens directly to dendritic cells with a viral vector could be the most immunogenic approach. Gritstone launched...
BC Week In Review | May 2, 2016
Company News

Celgene sales and marketing update

The U.K.’s NICE recommended against the use of Vidaza azacitidine from Celgene to treat patients at least 65 years of age who are not eligible for hematopoietic stem cell transplantation (HSCT) with acute myelogenous leukemia...
BC Week In Review | Nov 9, 2015
Clinical News

Vidaza azacitidine regulatory update

The European Commission approved a label expansion for Vidaza azacitidine from Celgene to include treatment of patients ages >=65 who are not eligible for hematopoietic stem cell transplantation (HSCT) with acute myelogenous leukemia (AML) with...
BioCentury | Oct 26, 2015
Finance

Neo is the time

With a resume that includes Pharmion Corp. and Clovis Oncology Inc. (NASDAQ:CLVS), Andrew Allen did not suffer from a lack of VC interest for his newest cancer venture. His Gritstone Oncology Inc. launched last week...
BC Extra | Oct 21, 2015
Top Story

Gritstone raises $102M series A

Gritstone Oncology Inc. (Emeryville, Calif.) raised $102 million in a series A round, the third-largest series A for a biotech this year. Versant Ventures and The Column Group led the round, which also included Clarus...
Items per page:
1 - 10 of 448
BC Innovations | Nov 7, 2019
Targets & Mechanisms

New cereblon substrates linked to thalidomide teratogenicity

A Celgene-funded study from Tokyo Medical University and the University of Milan has identified two new thalidomide-dependent CRBN substrates that could be applied to screens for new, safer thalidomide derivatives. Thalidomide and its analogs, collectively...
BC Extra | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

Tessa is hoping a JV with a Guangzhou biohub will speed access to the company’s virus-specific T cell therapies for cancers prevalent in China. The Singapore-based company, which partnered Thursday with GSGKC to develop and...
BC Extra | Aug 3, 2018
Preclinical News

Mechanism identified behind thalidomide-induced birth defects

Researchers at Dana-Farber Cancer Institute uncovered the mechanistic pathway by which thalidomide and two related analogs cause severe fetal harm, answering a long-held question about the three teratogenic drugs now used as cancer therapies. The...
BC Week In Review | May 18, 2018
Company News

FDA names, shames ‘anticompetitive’ drug companies

FDA Commissioner Scott Gottlieb Thursday made public a list of 41 branded drug companies that generics manufacturers have accused of blocking access to drug samples to thwart development of competitive generic drugs. The list includes...
BC Extra | May 17, 2018
Politics & Policy

FDA names, shames ‘anticompetitive’ drug companies

FDA Commissioner Scott Gottlieb Thursday made public a list of 41 branded drug companies that generics manufacturers have accused of blocking access to drug samples to thwart development of competitive generic drugs. The list includes...
BioCentury | May 23, 2016
Product Development

Provoking a response

Gritstone Oncology Inc. selected Immune Design Corp .'s ZVex technology to deliver personalized neoantigen therapies because targeting the antigens directly to dendritic cells with a viral vector could be the most immunogenic approach. Gritstone launched...
BC Week In Review | May 2, 2016
Company News

Celgene sales and marketing update

The U.K.’s NICE recommended against the use of Vidaza azacitidine from Celgene to treat patients at least 65 years of age who are not eligible for hematopoietic stem cell transplantation (HSCT) with acute myelogenous leukemia...
BC Week In Review | Nov 9, 2015
Clinical News

Vidaza azacitidine regulatory update

The European Commission approved a label expansion for Vidaza azacitidine from Celgene to include treatment of patients ages >=65 who are not eligible for hematopoietic stem cell transplantation (HSCT) with acute myelogenous leukemia (AML) with...
BioCentury | Oct 26, 2015
Finance

Neo is the time

With a resume that includes Pharmion Corp. and Clovis Oncology Inc. (NASDAQ:CLVS), Andrew Allen did not suffer from a lack of VC interest for his newest cancer venture. His Gritstone Oncology Inc. launched last week...
BC Extra | Oct 21, 2015
Top Story

Gritstone raises $102M series A

Gritstone Oncology Inc. (Emeryville, Calif.) raised $102 million in a series A round, the third-largest series A for a biotech this year. Versant Ventures and The Column Group led the round, which also included Clarus...
Items per page:
1 - 10 of 448